GB202016863D0 - Microrna-29 compounds, compositions and uses in therapy - Google Patents

Microrna-29 compounds, compositions and uses in therapy

Info

Publication number
GB202016863D0
GB202016863D0 GBGB2016863.9A GB202016863A GB202016863D0 GB 202016863 D0 GB202016863 D0 GB 202016863D0 GB 202016863 A GB202016863 A GB 202016863A GB 202016863 D0 GB202016863 D0 GB 202016863D0
Authority
GB
United Kingdom
Prior art keywords
microrna
therapy
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2016863.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Causeway Therapeutics Ltd
Original Assignee
Causeway Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Causeway Therapeutics Ltd filed Critical Causeway Therapeutics Ltd
Priority to GBGB2016863.9A priority Critical patent/GB202016863D0/en
Publication of GB202016863D0 publication Critical patent/GB202016863D0/en
Priority to CA3195977A priority patent/CA3195977A1/en
Priority to US18/033,322 priority patent/US20240390410A1/en
Priority to EP21801857.0A priority patent/EP4232580A2/en
Priority to CN202180087062.9A priority patent/CN116744942A/zh
Priority to KR1020237016847A priority patent/KR20230088810A/ko
Priority to JP2023549131A priority patent/JP2023547274A/ja
Priority to PCT/EP2021/079580 priority patent/WO2022084561A2/en
Priority to AU2021365394A priority patent/AU2021365394A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB2016863.9A 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy Ceased GB202016863D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB2016863.9A GB202016863D0 (en) 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy
CA3195977A CA3195977A1 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy
US18/033,322 US20240390410A1 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy
EP21801857.0A EP4232580A2 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy
CN202180087062.9A CN116744942A (zh) 2020-10-23 2021-10-25 Microrna-29化合物、组合物及其治疗用途
KR1020237016847A KR20230088810A (ko) 2020-10-23 2021-10-25 마이크로rna-29 화합물, 조성물 및 요법에서의 용도
JP2023549131A JP2023547274A (ja) 2020-10-23 2021-10-25 マイクロｒｎａ－２９の化合物、組成物、および治療法における使用
PCT/EP2021/079580 WO2022084561A2 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy
AU2021365394A AU2021365394A1 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2016863.9A GB202016863D0 (en) 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy

Publications (1)

Publication Number Publication Date
GB202016863D0 true GB202016863D0 (en) 2020-12-09

Family

ID=73726994

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2016863.9A Ceased GB202016863D0 (en) 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy

Country Status (9)

Country Link
US (1) US20240390410A1 (enExample)
EP (1) EP4232580A2 (enExample)
JP (1) JP2023547274A (enExample)
KR (1) KR20230088810A (enExample)
CN (1) CN116744942A (enExample)
AU (1) AU2021365394A1 (enExample)
CA (1) CA3195977A1 (enExample)
GB (1) GB202016863D0 (enExample)
WO (1) WO2022084561A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023445724A1 (en) * 2023-04-28 2025-11-06 Causeway Therapeutics Limited Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400598D0 (en) * 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
CA2949109A1 (en) * 2014-05-29 2015-12-03 Quark Pharmaceuticals, Inc. Methods and compositions for preventing ischemia reperfusion injury in organs
US9376681B2 (en) * 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
GB201503967D0 (en) * 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
US20200318113A1 (en) * 2019-03-05 2020-10-08 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof

Also Published As

Publication number Publication date
EP4232580A2 (en) 2023-08-30
CA3195977A1 (en) 2022-04-28
KR20230088810A (ko) 2023-06-20
US20240390410A1 (en) 2024-11-28
WO2022084561A3 (en) 2022-06-02
AU2021365394A1 (en) 2023-06-08
JP2023547274A (ja) 2023-11-09
WO2022084561A2 (en) 2022-04-28
CN116744942A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
GB202102895D0 (en) Novel compounds, compositions and therapeutic uses thereof
GB202304235D0 (en) Compositions, methods and uses
GB201915831D0 (en) Compounds, compositions and therapeutic uses thereof
GB2613256B (en) Compositions, and methods and uses relating thereto
GB202016863D0 (en) Microrna-29 compounds, compositions and uses in therapy
AU2021365394A9 (en) Microrna-29 compounds, compositions and uses in therapy
PT4027976T (pt) Composições de rifabutina e método de produção
GB2626637B (en) Compositions, methods and uses
GB201915828D0 (en) Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) Compounds, compositions and therapeutic uses thereof
GB202317463D0 (en) Compositions, methods and uses
GB2621686B (en) Compositions, and methods and uses relating thereto
GB2609091B (en) Compositions, and methods and uses relating thereto
GB202305630D0 (en) Compositions, methods and uses
GB202213163D0 (en) Novel compounds, compositions and therapeutic uses thereof
PL4028001T3 (pl) Sposoby leczenia ryfabutyną, zastosowania i kompozycje
GB202107977D0 (en) Method, composition and use
GB202110422D0 (en) Novel compositions having use in therapy
HK40082885A (en) Compositions, their uses in therapy and methods thereof
GB202013019D0 (en) Novel compositions having use in therapy
GB202415328D0 (en) Compositions, methods and uses
GB202405929D0 (en) Compositions, uses and methods
GB202311075D0 (en) Compositions, methods and uses
GB202306456D0 (en) Composition, methods and uses
GB202207859D0 (en) Compositions, methods and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)